You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-PD1/PDL1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Skin Health and Quality of Life in Patients Receiving

Not yet recruiting
  • Lung Cancer
  • +7 more
  • EQ-5D-5L questionnaire
  • +2 more
  • Roma, Italy
    Roberto Iacovelli
May 17, 2023

Urothelial Carcinoma Trial in Ann Arbor (Pembrolizumab, Abraxane)

Active, not recruiting
  • Urothelial Carcinoma
  • Ann Arbor, Michigan
    University of Michigan Comprehensive Cancer Center
Dec 15, 2021

Cancer Trial in Besancon (Biological samples, Anti PD1/PDL1 treatment)

Recruiting
  • Cancer
  • Biological samples
  • Anti PD1/PDL1 treatment
  • Besancon, France
    University Hospital of Besançon
Jul 30, 2021

Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

Not yet recruiting
  • Cervical Cancer
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023

SCLC,Extensive Stage Trial in Changchun (AK104 IV infusion;Chiauranib oral)

Not yet recruiting
  • SCLC,Extensive Stage
  • AK104 IV infusion；Chiauranib oral
  • Changchun, Jilin, China
    Jilin Province Cancer Hospital
Aug 16, 2022

Serial [18F]FluorodeoxyglucosePET/CT asBiomarker of Therapeutic

Terminated
  • Non-Small Cell Lung Cancer (NSCLC)
  • [18F]fluoroglucose(FDG)
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Mar 16, 2021

Solid Tumor Trial in Richmond (Stereotactic radiotherapy, Biological: humanized anti-PD-1 mAb, Biological: humanized anti-PD-L1

Completed
Has Results
  • Solid Tumor
  • Stereotactic radiotherapy
  • +2 more
  • Richmond, Virginia
    Virginia Commonwealth University/Massey Cancer Center
Dec 20, 2021

Immune Checkpoint Inhibitors (AUTENTIC)

Recruiting
  • Cancer
  • +2 more
  • Treatment with immune checkpoint inhibitors.
  • Blood tests.
  • Vitoria, Álava, Spain
    Hospital Universitario Araba
Aug 27, 2021

Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma Trial in Rochester (Anti-PD-L1 Monoclonal Antibody

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +3 more
  • Anti-PD-L1 Monoclonal Antibody IMC-001
  • Punch Biopsy
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Metastatic Renal Cell Carcinoma Trial in Milan (Cabometyx)

Completed
  • Metastatic Renal Cell Carcinoma
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale Tumori
Apr 23, 2021

Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)

Completed
  • Melanoma
  • +27 more
  • XmAb20717
  • Los Angeles, California
  • +16 more
Nov 29, 2022

HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With

Not yet recruiting
  • Gastric Cancer
  • Observational
  • (no location specified)
Dec 13, 2022

PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting
  • Non-small Cell Lung Cancer
  • Monza, Italy
    ASST-Monza Ospedale San Gerardo
Jun 9, 2022

Colon Adenocarcinoma, High-Frequency Microsatellite Instability, Metastatic Malignant Solid Tumor Trial in Houston

Active, not recruiting
  • Colon Adenocarcinoma
  • +10 more
  • Anti-PD-L1/TGFbetaRII Fusion Protein M7824
  • Houston, Texas
    M D Anderson Cancer Center
Jan 12, 2022

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

Recruiting
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Lyon, France
    Centre Léon Bérard
Nov 30, 2022

Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 Trial in Scottsdale,

Active, not recruiting
  • Advanced Lung Non-Small Cell Carcinoma
  • +7 more
  • Scottsdale, Arizona
  • +2 more
Nov 3, 2021

Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital Fudan university
Jan 31, 2023

Profiling of Circulating Immune Cells to Uncover Response

Not yet recruiting
  • Melanoma
    • (no location specified)
    Nov 23, 2023

    NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +4 more
    • MK-2870
    • +2 more
    • (no location specified)
    Sep 15, 2023

    NSCLC, Progression, Disease Trial in Paris (Resting Energy Expenditure measurement)

    Completed
    • Non-small Cell Lung Cancer
    • Progression, Disease
    • Resting Energy Expenditure measurement
    • Paris, France
      Cochin Hospital
    May 10, 2021

    Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Oligometastatic Disease
    • PD-1 combined with SBRT
    • Guangzhou, Guangdong, China
      Mian Xi
    Dec 18, 2022

    Solid Tumor Malignancy, Hematologic Malignancy, Leukemia Trial run by the NCI (mrna 1273 injection)

    Recruiting
    • Solid Tumor Malignancy
    • +4 more
    • mRNA-1273
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 14, 2023

    Locally Advanced or Metastatic Solid Tumors, NSCLC Trial in Australia (HLX301)

    Recruiting
    • Locally Advanced or Metastatic Solid Tumors
    • Non-small Cell Lung Cancer
    • Blacktown, New South Wales, Australia
    • +4 more
    May 25, 2022

    Melanoma (Skin), Cutaneous Melanoma, Adult Disease Trial in France, Spain, United States (ANV419, Pembrolizumab, Ipilimumab)

    Recruiting
    • Melanoma (Skin)
    • +4 more
    • Bloomington, Minnesota
    • +7 more
    Jan 31, 2023

    Immunotherapy, ADR Trial in Beijing

    Not yet recruiting
    • Immunotherapy
    • ADR
      • Beijing, Beijing, China
        Xuanwu Hospital
      Jan 27, 2023